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Abstract: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal types of tumours, and its
incidence is rising worldwide. Although survival can be improved by surgical resection when these
tumours are detected at an early stage, this cancer is usually asymptomatic, and disease only becomes
apparent after metastasis. Several risk factors are associated with this disease, the most relevant
being chronic pancreatitis, diabetes, tobacco and alcohol intake, cadmium, arsenic and lead exposure,
certain infectious diseases, and the mutational status of some genes associated to a familial component.
PDAC incidence has increased in recent decades, and there are few alternatives for chemotherapeutic
treatment. Endoplasmic reticulum (ER) stress factors such as GRP78/BiP (78 kDa glucose-regulated
protein), ATF6α (activating transcription factor 6 isoform α), IRE1α (inositol-requiring enzyme
1 isoform α), and PERK (protein kinase RNA-like endoplasmic reticulum kinase) activate the
transcription of several genes involved in both survival and apoptosis. Some of these factors aid in
inducing a non-proliferative state in cancer called dormancy. Modulation of endoplasmic reticulum
stress could induce dormancy of tumour cells, thus prolonging patient survival. In this systematic
review, we have compiled relevant results concerning those endoplasmic reticulum stress factors
involved in PDAC, and we have analysed the mechanism of dormancy associated to endoplasmic
reticulum stress and its potential use as a chemotherapeutic target against PDAC.
Keywords: pancreatic ductal adenocarcinoma; ER stress; GRP78; ATF6α; IRE1α; PERK; ATF4; P38;
UPR; dormancy
1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death in both sexes,
with an estimated 55,440 new cases of PDAC in United States in 2018 [1]. The incidence has increased
worldwide, especially in northern European countries and Canada [2]. Moreover, some studies have
estimated that pancreatic cancer would increase from the fourth to the second leading cause of cancer
deaths in the United States by 2020 [3]. In Europe, PDAC-related mortality has increased from 75,439
deaths in 2009 to approximately 82,300 in 2014 [4]. This rise has been hypothesised to be related
to the increase in the consumption of high-sugar or carbohydrate-rich foods [5]. The most crucial
acquired risk factors for pancreatic cancer sorted by relevance are cigarette smoking (hazard ratio
(HR) = 1.74), obesity (body mass index > 30; HR = 1.2–1.5), high alcohol consumption (HR = 1.1–1.5),
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and some infectious diseases that include Helicobacter pylori (HR = 1.5), Hepatitis B virus and Human
Immunodeficiency virus [6–8]. Interestingly, other studies suggested that high consumption of cooking
and table salt, and smoked food have been significantly linked with pancreatic cancer (p = 0.009,
p = 0.0001, and p < 0.01 respectively) [9]. Other observational studies associated pancreatic cancer
with cadmium, arsenic, and lead exposure [10]. Indeed, those European countries with the highest
levels of arsenic (more than 10 µg/L [11]), that include Finland, Austria, Czech Republic, Slovakia,
and Hungary are those with highest incidence of pancreatic cancer [12].
It is estimated that 5–10% of PDAC cases present a hereditary component [13]. BRCA2 is the
most commonly mutated gene in familial PDAC [14]. PALB2 is considered to be another relevant
PDAC susceptibility gene [15], and it has been described that PALB2 protein binds to BRCA2 protein
and contributes to its function [16]. Germline alterations in ataxia telangiectasia mutated (ATM) gene
have also been identified in hereditary PDAC patients [17]. Some familial syndromes also constitute
risk factors for PDAC development [18]. Mutations in the PRSS1 gene are responsible for hereditary
pancreatitis, with a cumulative risk of developing PDAC of 40–55% [19]. Germline mutations in the
LKB1/STK11 tumour suppressor gene cause Peutz-Jeghers Syndrome (PJS). PJS patients have an 11–36%
increased risk to develop several tumour types, including PDAC [20]. Familial adenomatous polyposis
(FAP) is caused by inactivating mutations in APC and MUTYH, and it is considered a risk factor for
hereditary PDAC [19]. Lynch Syndrome is caused by alterations in mismatch repair genes: MLH1,
MSH2, MSH6, and PMS2, and it shows a cumulative risk of 4% for PDAC [21].
High throughput genetic profiling platforms are powerful tools for analysis of whole DNA, RNA,
and non-coding RNA, especially microRNA and long non-coding RNA [22]. The mutational status of
BRCA2 is one of the most useful predictive biomarkers in clinical practice [23]. Concerning micro-RNAs,
the overexpression of miR-21 was associated with a shorter disease-free survival in patients who
received adjuvant gemcitabine after surgical resection [24], and miR-21 overexpression predicts
resistance to 5-fluorouracil [25]. Furthermore, high miR-21 levels in plasma were associated with poor
outcome in patients treated with induction chemotherapy followed by chemoradiotherapy [26].
PDAC diagnosis is usually late because the disease is often asymptomatic in early stages,
and the first symptoms, such as abdominal pain and nausea, are usually managed in outpatient
care. Also, diabetes has been associated with pancreatic cancer emergence, and it could be used as
an early diagnosis biomarker (HR = 1.4–2.2) [27]. Complementary tests are performed when cholestasis,
intestinal obstruction, or pancreatitis occur [28]. Prognosis is usually poor, with a 5-year survival of
only 8% [29]. Survival can be improved when tumours are detected at early stages; indeed, it has
been reported that 5-year survival rate is 50% when tumours are <2 cm [30], and close to 100% for
tumours < 1 cm [31]. However, lesions < 1 cm or between 1 and 2 cm often go unnoticed on computed
tomography (CT) or magnetic resonance imaging (MRI) scans.
Surgical resection is currently the best option to improve survival [32]. The mean life expectancy
for pancreatic cancer is 1.4 years, reaching 3.5 years for surgically resected patients vs. 0.8 years for
non-operated patients (p < 0.001) [33]. Resection criteria are described in the National Comprehensive
Cancer Network (NCCN) guidelines [34]. After optimal resection (R0), the grade of cellular dysplasia
usually determines the prognosis. However, other clinical variables such as pT, pN, pM, or the tumour
stage may act as a prognostic tool in unresectable tumours [35].
Gemcitabine monotherapy was established as the first standard of care, due to the greater
clinical benefit compared to 5-FU in alleviation of some symptoms [36]. However, its small survival
improvement made it necessary to use gemcitabine in combination with platinum compounds [36].
Those compounds widely used in clinical practice are cisplatin, carboplatin, and oxaliplatin. They form
DNA adducts, and especially crosslink DNA, which triggers the apoptosis cascade [37]. The expression
of hENT1, which manages transport of gemcitabine and metabolically activate it, seems to be related
to gemcitabine response. However, different antibodies used to determine hENT1 expression by
immunohistochemistry demonstrated varying levels of predictivity of survival [38].
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Dealing with locally advanced pancreatic cancer, a phase II trial suggested that a capecitabine-based
regimen as induction chemotherapy is preferable in combination with radiation (50 Gy in 28
fractions) [39].
For metastasic PDAC, a combination chemotherapy regimen consisting of folinic acid, 5-FU,
irinotecan and oxaliplatin (FOLFIRINOX) has demonstrated not only an increase in overall survival
(p < 0.001), but also an increase in progression-free survival (p < 0.001), and in the objective response
rate (p < 0.001) compared with gemcitabine as a first-line therapy. Nevertheless, the safety profile of
FOLFIRINOX was less favourable than that of gemcitabine [40]. Other options of treatment for patients
with metastatic disease and good performance status (0 or 1) include nab-paclitaxel. Paclitaxel destroys
cancer cells by preventing the normal breakdown of microtubules during cell division, and albumin
transports paclitaxel across the endothelial cell and concentrates it in the tumour. The combination of
gemcitabine plus nab-paclitaxel extended the median overall survival (OS) of patients compared to
gemcitabine alone, after 2 months [41].
Other chemotherapeutic approaches for those patients with presence of BRCA2, PALB2, ATM,
or mismatch repair (hMLH1 and MSH2) gene mutations are poly-ADP ribose polymerase (PARP)
inhibitors, which subsequently cause an impair in DNA damage repair [42]. Remarkably, neoadjuvant
iniparib plus gemcitabine induced a complete pathological response in a patient with recurrent PDAC
harboring the BRCA2 mutation [43]. However, in a phase I study of olaparib plus gemcitabine in
patients with advanced solid tumours, which included 15 patients with PDAC, no differences were
found in terms of efficacy [44].
Tumour cells can activate quiescent endothelial cells by overexpression of pro-angiogenic factors
like vascular endothelial growth factor (VEGF) [45]. Nevertheless, anti-angiogenic therapy based
on bevacizumab either in combination with gemcitabine or gemcitabine plus erlotinib has been
unsuccessful for the treatment of metastasic PDAC [46].
Immunotherapy based on immune checkpoint inhibitors has risen to the forefront of therapeutic
strategies against some solid tumors. Unfortunately, monotherapy with anti-CTLA4 monoclonal
antibodies was ineffective in the treatment of locally advanced or metastatic PDAC [47].
More recently, the use of nanoliposomal irinotecan in combination with 5-fluorouracil/folinic acid
has shown an improvement of OS over 5-fluorouracil/folinic acid alone (6.1 vs. 4.2 months), and it
may constitute an active and tolerable second-line treatment option [48].
Nevertheless, patients could present acquired resistance to these chemotherapies due to the
accumulation of secondary genomic alterations [49]. Thus, the identification of new therapeutic targets
becomes a critical necessity for increase patients’ survival. PDAC is an aggressive tumour, and the
similarity between 5- and 15-year survival rates suggests that the disease does not generate dormant
cells [50]. Therefore, the therapeutic induction of dormancy may lengthen the survival of patients in
future, and that is where targeting endoplasmic reticulum stress could come in.
Endoplasmic reticulum (ER) stress pathways have turned into a target in the effort to modulate
the apoptosis of cancer cells. The objective of the present review is to increase the understanding of
ER stress response factors as potential targets for PDAC treatment. Therapies based on drugs that
could modulate these ER stress response proteins would open new routes for the management of
PDAC patients.
A literature search of PubMed database (U.S. National Institutes of Health’s National Library of
Medicine) was conducted to obtain research articles. Keywords such as ER stress response, unfolded
protein response, PDAC treatment, GRP78, ATF6α, IRE1α, PERK, ATF4, and P38 were used in the
computer-assisted literature search. After the articles were imported, the results from the studies
were merged, with a total of 1220 articles retrieved. Of them, 1148 articles were excluded manually
because they were unrelated to cancer (n = 141), unrelated to ER stress factors (n = 873), or had no
treatment involvement (n = 62). Of the remaining 72 articles, 15 studies were excluded, and 57 met
the inclusion criteria for showing both qualitative and quantitative data. Then, these 57 articles were
critically appraised for the present ER stress review. The rest of the 49 citations were included for
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PDAC introduction. From each report, the following information was subsumed for the present
systematic review: type of neoplasia studied, ER stress factor involved, description of such in vitro
and/or in vivo approaches, treatment used and doses, statistical significance, molecular pathway
involved, and most relevant conclusions.
All types of research articles that met the criteria of this review were included in the study
regardless of whether the results were positive, negative, or null.
2. Endoplasmic Reticulum Stress Response in PDAC
Endoplasmic reticulum stress induces a signaling pathway that increases protein folding
capability to maintain cell homeostasis. This response to stress is also called the unfolded protein
response (UPR) or ER stress response (ERSR). Hypoglycemia and hypoxia also activate an ERSR,
which physiologically generates mechanisms to prevent increased cell damage and avoid apoptosis.
Nevertheless, if homeostasis cannot be restored and the cell is subjected to chronic stress, generalised
apoptosis will be triggered [51]. ERSR involves three mechanisms: (i) transcription of the chaperone
GRP78 to support protein folding; (ii) reduction of translation activity to minimise the quantity
of unprocessed protein; and (iii) degradation of the accumulated unfolded proteins through the
ubiquitin-proteasome pathway [52,53]. These three mechanisms are controlled by three transmembrane
sensors in the ER, namely PERK, IRE1α, and ATF6α, which remain inactive while they are binding
to the ER chaperone GRP78 [53]. PERK directly induces ATF4 and eIF2α, IRE1α activates XBP1,
and ATF6α leads the activation of the JNK and Rheb/mTOR pathways (Figure 1).
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Under ER stress conditions, unfolded proteins bind to GRP78. Then, GRP78 unbinds from
these ER stress sensors and ERSR is triggered to prevent apoptosis and promote cell survival [54].
Nevertheless, some studies have shown that when ER functions cannot be restored by ERSR, long-term
stress triggers apoptosis through CHOP activation [54,55]. Subsequently, ERSR promotes survival,
and therefore it has been closely related to cancer development and progression [56].
GRP78 expression remains at low baseline levels in untransformed somatic cells; however,
it is overexpressed in PDAC cells, and it has been associated with poor prognosis and tumour
chemoresistance (Tables 1 and 2) [57,58]. Tissue microarray-based immunohistochemistry with tumour
and normal tissue from 180 PDAC patients showed that GRP78 expression was significantly increased
in cancer cells compared to non-tumour tissue (p < 0.05). This highest expression of GRP78 was
associated with a highest T-stage and poor overall survival (p < 0.05). In contrast, GRP78 silencing
with small interfering RNAs (siRNAs) in PDAC cell lines decreases proliferation, invasion and
migration [57]. In other study, GRP78 expression in PDAC cell lines was associated with invasive
potential. Its overexpression in PDAC cell lines activated FAK and JNK that promoted invasion,
and its downregulation inhibited the invasive potential [58]. Moreover, GRP78 plays an important
role in chemoresistance. GRP78 downregulation with siRNAs in combination with chemotherapeutics
increased cell death compared to treatment or individual silencing. GRP78 downregulation also
decreased ABC transporter activity, sensitising the PDAC cells to several chemotherapeutic agents [59].
GRP78 overexpression contributed to tumour angiogenesis independently of vascular endothelial
growth factor (VEGF) and it increased AKT phosphorylation and ERK1/2 activation [60]. In fact,
GRP78 knockout mice showed a severe reduction of angiogenesis and tumour growth without any
effect on normal tissue [61]. In other types of cancer, GRP78 has also been associated to tumour
malignancy. Its suppression caused CD24 downregulation and enhanced human colorectal cancer
cells sensitisation to oxaliplatin [62]. In addition, GRP78 inhibition with plumbagin contributed to
apoptosis induction and sensitised cells to tamoxifen in breast cancer [63]. GRP78 targeting with
antibodies exhibited a decrease in cell proliferation and tumour growth, apoptosis induction and
improved efficacy of radiation therapy in human glioblastoma and non-small cell lung cancer [64].
Under ER stress, the activation of the PERK-eIF2α-ATF4-CHOP pathway triggers apoptosis and
has been proposed as a new alternative to induce apoptosis by ER stress induction in pancreatic cell
lines and mice models (Figure 1, Table 1) [55,65,66]. To counteract ER stress, PERK activates EIF2α by
phosphorylation, which inhibits protein translation and reduces the influx of unfolded proteins into
the endoplasmic reticulum; thus, PERK promotes pro-oncogenic capabilities [67]. It has been reported
that PERK contributed to proliferation and angiogenesis in low-grade pancreatic neuroendocrine
tumour models [68] (Table 1). Moreover, PERK enhanced invasion and metastasis in murine models of
breast cancer, and it has been associated with poor prognosis of breast, lung, and gastric cancer [69]
(Table 2).
Another factor activated by PERK is the transcription factor ATF4. It has been previously described
that the role of ATF4 is related to tumour cell survival [70]. In haematological malignancies, ATF4
has been used as a target for treatment against cultured and primary cancer cells lines, and mice
models [71,72] (Table 2). In colorectal cancer, overexpression of ATF4 has been related to oxaliplatin
and 5-fluorouracil resistance [73], while ATF4 downregulation delayed tumour growth of endometrial
cancer xenografts [74] (Table 2). ATF4 has also been found to be overexpressed in pancreatic
neuroendocrine tumours [75]. Interestingly, ATF4 protein levels were increased after gemcitabine
treatment in PDAC cell lines; therefore, ATF4 downregulation has been proposed as an additional
mechanism to induce apoptosis in combination with gemcitabine [76].
IRE1 is another factor that is responsible for activating ERSR. In mammals there are two isoforms:
IRE1α, which is ubiquitously expressed, and IRE1β, which is restricted to the respiratory and
gastrointestinal tract [51]. Activation of IRE1α promotes the transcription factor X-box 1 (XBP1),
which also induces the transcription of other ERSR genes (Figure 1) [51,54]. It has been reported that
XBP1 is overexpressed in PDAC cell lines [77]. It has been suggested that the inhibition of IRE1α/XBP1
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could be a target for future treatments for anticancer therapies [78]. Indeed, IRE1α induces the
JNK pathway to conduct apoptosis through two mechanisms: nuclear translocation of c-Jun and
activation, and overexpression of pro-apoptotic factors that include TNFα, FAS-L, and BAK2 [79]; and
mitochondrial translocation of JNK, which cleaves BID, and activates the intrinsic apoptosis cascade
(Figure 1). Moreover, JNK inhibits BCL2 family proteins, thus avoiding the anti-apoptotic properties
of these proteins [80]. The use of IRE1α to induce apoptosis as a target for cancer management
has been demonstrated in several pre-clinical studies. In acute myeloid leukemia, downregulation
on IRE1α reduced cell viability, increased apoptosis ratio, and led to cell cycle arrest of tumour
derived cell lines and primary cell lines [81]. Moreover, it has been reported that high levels of XBP1
suppressed an aggressive phenotype of breast cancer-derived stem cells [77] (Table 2). XBP1 offers
an immunotherapeutic potential to induce CD3+CD8+ cytotoxic T lymphocytes against breast, colon,
and pancreatic cancer [82]. In fact, the regulation of IRE1/XBP-1 increased drug sensitivity and
decreased cell proliferation in breast cancer-derived cell lines and in mice models [83,84] (Table 2).
However, to our knowledge, there are no studies of IRE1α that are directly related to pancreatic cancer.
ATF6 is another factor that is necessary to induce ERSR. ATF6 has two isoforms: α and β; however,
it has been reported that ATF6β did not play a significant role in ERSR [85].
ATF6α is activated in the Golgi apparatus [86,87], is translocated to the nucleus, and stimulates
transcription of survival genes to neutralise ER stress, avoiding apoptosis and promoting cell
survival [85,88] (Figure 1). Moreover, ATF6α is considered an important promoter of VEGF to induce
angiogenesis [89]. In pancreatic neuroendocrine tumours, downregulation of ATF6α is able to induce
apoptosis through P38 activation [90] (Table 1). Our group has previously reported a two-protein
signature based on high expression of ATF6α and low expression of active form of P38, which was
associated with a high risk of recurrence in PDAC (HR = 3.256; 95% CI, 1.283–8.266; p = 0.013).
Multivariate analysis revealed that a combination of high expression of ATF6α and a low expression
of phospho-P38 was associated with a poor outcome for PDAC patients (HR = 2.705; p = 0.023),
together with tumour grade (HR = 2.886; p = 0.029) [91] (Table 1). Concerning other types of tumours,
a high expression of ATF6α has been involved in chemoresistance of leukemia-derived cell lines to
imatinib [92], and it was necessary for the survival of melanoma-derived cell lines under ER stress
conditions [93] (Table 2).
3. ERSR to Induce Dormancy in PDAC
One of the most crucial activated pathways in PDAC involves mitogen-activated protein kinases
(MAPKs), which promote survival and induce proliferation [94]. However, some of the MAPK factors
such as JNK and P38 negatively regulate cell cycle progression and induce cell death [95]. Expression
of P38 limits cell-line growth by negative regulation of the cycle in the G1/S and G2/M transitions;
pharmacologic inhibition of P38 was able to increase tumour cell proliferation in vitro and in xenografts.
However, JNK inhibition was able to antagonise the effects of P38 inhibition [96]. Therefore, the role of
P38 has been closely related to an apoptotic phenotype. In fact, it has been reported that high levels of
P38 are correlated with longer survival in PDAC patients [91] (Table 1). In other tumour types like
colorectal and breast cancer, the drug-specific activation of P38 selectively inhibited the self-renewal of
cancer stem cells (CSC) through a reversal of stem cell markers (CD44 and CD133) and self-renewal
factors (c-MYC and BMI-1). Thus, this study corroborated the recognised role of P38 as a tumour
suppressor [97].
Interestingly, P38 is also involved in stem cell dormancy. This means that tumours release
disseminating cells in a quiescent state that lodge in other organs, albeit in the initial stages, which
will develop distant metastasis even after resection of the primary tumour [98,99]. This mechanism is
used by cancer cells to become refractory to targeted or conventional therapies, and to prolong their
survival by interactions with other different cell populations such as endothelial cells, immune cells,
stromal cells, or fibroblasts [100].
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P38 phosphorylation contributes to the nuclear translocation and activation of ATF6α in
dormant cancer cells through the ATF6α/Rheb/mTOR pathway (Figure 1). The ERSR sensor
ATF6α promotes survival through Rheb overexpression and activation of mTOR signalling pathways
independently of AKT. Moreover, the interaction between ATF6α and mTOR signaling conferred
resistance to doxorubicin and rapamycin, showing a mechanism of chemoresistance. Indeed, Schew
and Aguirre-Ghiso reported that downregulation of ATF6α prolonged the survival of nude mice
bearing dormant tumour cells [99].
Activation of P38 inhibits ERK1/2, which induces cell cycle inhibitors P27 and P21, keeping the
cell in G0–G1 phase, which is crucial for maintaining a dormant phenotype [98]. Furthermore, P38
inhibits tumour transformation by oxidative stress [101] and it also cooperates with ERK1/2 to induce
the quiescence of tumour cells [102].
ATF6α is expressed even in non-stress conditions, and it is necessary to maintain GRP78
expression. Indeed, ATF6α mRNA levels increased when ER stress was induced with ER
stress-triggering drugs such as tunicamycin, thapsigargin, dithiothreitol (DTT), or high glucose
concentration. ATF6α downregulation with small interfering RNA reduced GRP78 expression,
and raised susceptibility to cell death. Thereby, β-cell apoptosis increased in ATF6α-depleted cells in
either control or ER stress conditions [90] (Table 1).
There are currently no studies showing a direct relationship between ATF6α and dormancy of
PDAC. In other tumour types, ATF6α overexpression has been proposed to be a target against cancer
stem cells (CSC), due to the nuclear translocation of ATF6α under the effect of tunicamycin in CSC
population [77] (Table 2). Recently, heparan hexasaccharide sulfate has been used with favourable
results, selectively inhibiting CSC from PDAC and other solid tumours by activation of P38 [97]
(Tables 1 and 2). Although there are studies with promising results concerning PDAC, there is still
a lack of evidence to justify the use of ERSR activation as a target for proliferative pancreatic cancer
and stem cells. Nevertheless, the ERSR could be a potential pathway to increase patient survival.
Other tumours like prostate cancer, melanoma, or breast cancer show the highest 5-years survival
rates (100, 93, or 90%, respectively) but survival decreases to ~20% at 15-years [50]. In these cases,
dormant tumours cells could be present to generate metastasis years later. Translational research
community wonders whether the “awakening” of dormant cells may or not facilitate their elimination
with standard chemotherapies. However, the genetic heterogeneity of dormant cells suggests that
treatments may not be as effective as was originally intended. In the case of PDAC, it has a 5-year
survival rate of 6%, and survival is relatively unchanged at 10 and 15 years. This survival rate suggests
that PDAC does not present dormancy. Then, dealing with PDAC, the implementation of a drug to
induce dormancy would be the most effective strategy to longer survival rates and a delay in the
appearance of metastases.
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Table 1. Pre-clinical studies with ER stress response factors against pancreatic ductal adenocarcinoma.
Factor Material Treatment (Concentration) ER Stress Factors Involved p Brief Ref
ATF6 45 patient samples (stage II and III) none ATF6α/P38 =0.013 ATF6α high expression and P38 lowexpression associates with poor outcome [91]
GRP78
180 patient samples (stage I, II
and III) none GRP78/CDK4/CDK6/STAT3/JAK2/RhoA <0.05
GRP78 overexpression associates with
poor outcome [57]
Cell lines (MIA PaCa-2, S2-VP10,
SU.86.86)
Gemcitabine (400 nm), paclitaxel (50 nm), 5-FU (5 µm),
GRP78 small interfering RNA (siRNA) GRP78/ABC transporters <0.001
GRP78 downregulation diminishes
chemoresistance and increases apoptosis
when combined with chemotherapeutics
[59]
Cell lines (Panc-1, CFPAC1,
MIA-PaCa-2, Panc2.03, Panc02).
Mouse samples (Panc-1 xenograft;
Panc02 orthotopic implantation)
Cell lines: Erastin (2.5–40 µm), GRP78 short hairpin
RNA (shRNA), ATF4 shRNA. Mice models:
gemcitabine (20 mg/kg), sulfasalazine (SAS;
100 mg/kg/i.p.), gemcitabine + sulfasalazine,
or gemcitabine + sulfasalazine + liproxstatin-1
(10 mg/kg/i.p)
ATF4/GRP78/GPX4 0.05
GRP78 decreases ferroptosis and limits
gemcitabine sensitivity both in vitro and
in vivo
[103]
Mice models (Pdx1-Cre; KrasG12D/+;
p53f/+)
GRP78 genetically modified mice GRP78 <0.01
GRP78 haploinsufficiency suppresses
acinar-to-ductal metaplasia and
tumorigenesis
[104]
Cell lines (BxPC-3, Panc-1, Capan-1,
Capan-2, CFPAC-1, HPAF-II,
AsPC1). Mouse models (xenografts
via subcutaneous injection)
ONC212 (cell lines: 20 µm; mice: 50 mg/kg) GRP78/IGF1-R <0.05
ONC212 shows an anti-proliferative
effect and induces apoptosis, reducing
tumour growth by inducing UPR
[105]
PERK
Cell lines (BxPC3). Mouse models
(human tumour xenografts)
Cells lines: GSK2656157 (1 µmol/L), tunicamycin
(5 µg/mL) and thapsigargin (1 µmol/L). Mice:
GSK2656157 (50 or 150 mg/kg, orally)
PERK/EIF2α/ATF4/CHOP <0.05
PERK inhibition as a potential
anti-tumour and
anti-angiogenic approach
[65]
Cell lines (Panc-1, PK1, KLM1) Avarol (40 µm) GRP78/PERK/EIF2α/CHOP <0.01 Avarol induces apoptosis via CHOP [55]
P38
35 patient samples (stage I, II, III and
IV). Cell lines (Panc5.04, Panc2.5,
HPNE-E6/E7, HPDE). Mouse
models (xenografts)
Cells lines: 5, 10, or 20 µmol/L. In vivo: intraperitoneal
injection of SB202190 (2.5 mg/kg/day), and SP600125
(40 mg/kg/day)
P38/JNK =0.041 Active P38 contributes to better outcome [96]
Cell lines (Panc-1), and derived
cancer stem cells Heparan sulfate hexasaccharide (100 µm) P38/TCF4 <0.005
P38 activation inhibits cancer stem cells
self-renewal inhibition [97]
ATF4
Cell lines (AsPC-1, Panc-1) ISRIB (250 nm), Gemcitabine (1 µm), ATF4 siRNA EIF2/ATF4/CHOP <0.01 ATF4 downregulation induces apoptosisin combination of gemcitabine [76]
Cell lines (Panc-1, HepG2, MIA
PaCa-2) Acriflavine (2.5 µm) PERK/eIF2α/ATF4 <0.001
Acriflavine restores drug sensitivity by
blocking UPR and EMT [106]
PERK/ATF6 Mouse models (BxPC-3 xenografts) Tanshinone IIA (0, 30 or 90 mg/kg) PERK/ATF6/caspase-12/IRE1α/elF2α/p-JNK/CHOP/caspase-3 <0.001
Tan-IIA promotes apoptosis by
induction of ER stress [66]
ATF6: activating transcription factor 6; GRP78: 78 kDa glucose-regulated protein; PERK: protein kinase RNA-like endoplasmic reticulum kinase; ATF4: activating ranscription factor 4;
UPR: unfolded protein response; EMT: epithelial-mesenchymal transition; ER: endoplasmic reticulum; Ref: references.
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Table 2. Pre-clinical studies with ER stress response factors in other solid tumours and haematological malignancies.
Factor Disease Material Treatment (Concentration) ER Stress Factors Involved p Brief Ref
ATF4
Pancreatic
neuroendocrine
tumour
45 patient samples - GRP78/ATF4/CHOP <0.05 ATF4 is overexpressed in pancreaticneuroendocrine tumours [75]
MCL and AML
MCL cell lines (Z-138, JVM-2,
MINO, and JeKo-1). AML cell lines
(OCI-AML3, MOLM-13, HL-60,
and THP-1). Primary cells.
Mouse models (via tail vein injection)
ONC201 (5 µm), rapamycin (10 nm),
or tunicamycin (1 µm) ATF4/mTORC1 <0.0001
ONC201 induces apoptosis independent of
TP53 mutation status and causes changes in
gene expression similarly by UPR. ONC201
induces ATF4 and inhibits mTORC1
[71]
ATF4-ATF3-
CHOP TLL
TLL cell lines (Jurkat, Molt4) and the
T-cell hybridoma cell line (DO11.10) Farnesol (75 µm) ATF4/ATF3/CHOP/PERK-eIF2α <0.01
Farnesol induces apoptosis in leukemic
cells by induction of the
PERK-eIF2α-ATF3/4 cascade
[72]
ATF4 CRC CRC cell lines (HCT116 and LoVo) Glucose deprivation(1,5 mmol/L glucose) GRP78/PERK/ATF4 <0.001
Glucose deprivation protects cells from
oxaliplatin- and 5-fluorouracil-induced
apoptosis, and induces the expression of
ATF4. Depletion of ATF4 can induce
apoptosis and drug re-sensitisation.
[73]
ATF6
Insulinoma Cell lines isolated from rat andmouse pancreas (INS-1 832/13)
Tunicamycin (0.1 µg/m),
thapsigargin (0.1 µg/m),
staurosporin, SB239063 (50 µm),
and SP600125 (50 µm), ATF6α siRNA
GRP78/ATF6α <0.05
ATF6α knockdown activates JNK and P38 to
induce apoptosis in insulinoma cells and
primary islets
[90]
OC and CML OC cell lines (HeLa), and CML celllines (K562 and LAMA)
Dithiothreitol (1 mm), thapsigargin
(500 nm), azetidine-2-carboxylic acid
(10 mm), and tunicamycin (5 µg/mL)
PDIA5/ATF6/BiP <0.01 PDIA5/ATF6α axis modulates sensitivity ofleukemia cells to imatinib [92]
IRE1α AML
AML cell lines (NB4, U937, K-562,
TF-1, HL-60, PL-21, and THP-1).
Primary samples and murine
hematopoietic cells
2-hydroxy-1-naphthaldehyde
(25 µm), STF-083010 (50 µm),
and toyocamycin (500 nm)
IRE1α/XBP1 <0.01
Inhibition of IRE1α decreases cell viability
and induces apoptosis and G1 cell
cycle arrest
[81]
IRE1/ATF6 Melanoma Melanoma cell lines (Mel-RM,Mel-RMu, Mel-CV, and MM200)
siRNA and shRNA of IRE1α
and ATF6 IRE1α/ATF6 <0.05
IRE1α and ATF6 are critical for survival of
melanoma cells undergoing ER stress [93]
IRE1/XBP1
BC BC cell lines (MDA-MB-231 andMCF-7)
Thapsigargin (250 nm) or bortezomib
(100 nm) IRE1/XBP-1 <0.05
Estrogen receptor β sensitises BC cells to
thapsigargin and to bortezomib by
regulating the IRE1/XBP-1 pathway
[83]
BC
BC cell lines (SUM159, BT549,
and MDA-MB-231), PDX models,
and genetically engineered
mouse models
Small molecule inhibitor 8866
(300 mg/kg oral daily) IRE1/XBP1 pathway and MYC <0.001
Silencing of XBP1 selectively blocks the
growth of MYC-hyperactivated cells.
Pharmacological inhibition of IRE1
selectively restrained MYC-overexpressing
tumour growth in vivo in a cohort of
preclinical patient-derived xenograft models
and genetically engineered mouse models
[84]
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Factor Disease Material Treatment (Concentration) ER Stress Factors Involved p Brief Ref
XBP-1 BC CSC derived from MCF7 cell line(CD44+/CD24-) Tunicamycin (2 µg/mL) XBP-1/ATF6/CHOP <0.001
Tunicamycin inhibited invasion, increased
cell death, suppressed proliferation,
and reduced migration in a CD44+/CD24-
and CD44+/CD24- rich MCF7 cell culture by
an increased level of spliced XBP-1,
ATF6 nuclear translocation and CHOP
protein expression
[77]
P38α/β CRC and BC
CRC cell lines (HT29, HCT116,
and LS174T) and BC cell lines
(MDA-MB-231)
Heparan sulfate hexasaccharide
(100 µm) TCF4 <0.005
Heparan sulfate hexasaccharide selectively
inhibits CSC self-renewal and induces
apoptosis in colorectal and breast CSCs
[97]
GRP78
CRC CRC cell lines (HT29, HT8, SW480and colo205)
Oxaliplatin (5 µm) and vomitoxin
(1 µg/mL) GRP78/CD24 <0.001
Suppression of GRP78 sensitises human
colorectal cancer cells to oxaliplatin by
downregulation of CD24
[62]
BC BC cell lines (MCF-7 and T47D) Plumbagin (from 0.5 to 5 µm) andTamoxifen (1 or 5 µm) GRP78/BIK < 0.05
Plumbagin inhibits GRP78 activity,
and increases Bik expression and apoptosis
induction, which contributes to the
sensitisation of BC cells to tamoxifen
[63]
NSCLC and GB
NSCLC cell lines (A549, and H460),
and GB cell lines (D54 and U251).
Mouse xenografts.
Anti-GRP78 antibody (1 µg/mL) GRP78 and PI3K/AKT/mTORsignaling <0.0001
Anti-GRP78 attenuates cell proliferation,
enhances radiation therapy, induces
apoptosis, and delays tumour growth in
mouse xenograft through the suppression of
Akt/mTOR signaling
[64]
PERK
Insulinoma Mice samples (insulinoma generatedby SV40 Large T-Antigen)
ISRIB (250 nm), Gemcitabine (1 µm),
ATF4 siRNA PERK <0.000005
PERK promotes tumour proliferation
and angiogenesis [68]
Breast, lung and
gastric cancer
BC cell lines (MCF7, T47D, BT474,
BT549, ZR-75–30, Hs578T,
MDA-MB-157, and MDA-MB-231).
Orthotopic injection into a mammary
pad on NOD/SCID mice.
Breast, lung and gastric cancer
patient samples.
AEBSF (1 mg) PERK/CREB3L1/ATF4 < 0.01
PERK signalling drives invasion and
metastasis of breast cancer cell lines through
CREB3L1, and associates with a poor
outcome in breast, lung, and gastric
cancer patients
[69]
AML: acute myeloid leukemia; BC: Breast cancer; CML: chronic myeloid leukemia; CSC: Cancer stem cell; CRC: Colorectal cancer; EC: endometrial cancer; ER: endoplasmic reticulum;
GB: Glioblastoma; NOD/SCID: non-obese diabetic/severe combined immunodeficiency; NSCLC: non-small cell lung cancer; MCL: mantle cell lymphoma; OC: Ovarian Cancer;
PDX: patient-derived xenograft; TLL: T lymphoblastic leukemia; UPR: unfolded protein response; Ref: references.
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4. Conclusions
ERSR is a molecularly well-known mechanism that has recently been used for different treatment
approaches in several types of cancer aimed both at proliferating and dormant tumour cells. Some of
these strategies are directly related to ERSR factors, but others are indirectly associated with this
molecular pathway, as in the case of P38. Regarding PDAC, few reliable data are available concerning
ERSR. Additionally, current research is mainly focused on in vitro models, and even less frequently
performed with in vivo models testing interference RNA-based technology. Therefore, until new
specific targeted therapies appear to design future clinical trials, it will not be able to evaluate the real
impact on patient’s survival. In fact, clinical trials to perform the validation of these pre-clinical results
are generally limited, due to the low incidence of this kind of tumour.
It has been suggested that there are several ways to trigger apoptosis and to induce response to
anti-tumour drugs. Those mechanisms include several pathways. One of them is the induction of
ER stress by the inhibition of GRP78/BiP unbinding from transmembrane sensors PERK, ATF6α,
and IRE1α. Out of these, GRP78 is the most widely studied protein that is related to the ER
stress response.
The knowledge of ERSR is leading to new studies, which allows the generation of potential
targeted therapies for those cancers with limited treatment options, such as PDAC. Forcing the cell into
a chronic state of ER stress or restraining its response via ATF6α/JNK, IRE1α/JNK, or PERK/CHOP
pathways could be a promising approach to achieve cell cycle arrest, apoptosis, and chemosensitivity,
and to reduce invasive phenotype and angiogenesis.
On the other hand, the induction of dormancy is not a phenomenon that is widely studied in
cancer, let alone in PDAC. Therefore, further studies are needed to be able to induce an effective
and sustained cell dormancy. From our point of view, modulation of dormancy in disseminated
proliferative tumour cells with adjuvant targeted therapies after R0 resection could be a potential
successful treatment option to delay the emergence of distant metastases, and to prolong PDAC
patients’ survival.
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Abbreviations
The following abbreviations are used in this manuscript:
ATF6α activating transcription factor 6 isoform α
AKT AKT serine/threonine kinase
ATM Ataxia telangiectasia mutated
CHOP CCAAT/enhancer binding protein (C/EBP)-homologous protein
CI confident interval
CSC cancer stem cells
GRP78 78 kDa glucose-regulated protein
CT computed tomography
eIF2α eukaryotic initiation factor 2 isoform α
EMT epithelial-mesenchymal transition
ER endoplasmic reticulum
ERK extracellular signal-regulated kinase
ERSR endoplasmic reticulum stress response
FAP Familial adenomatous polyposis
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HR hazard ratio
IRE1 inositol-requiring enzyme 1
JNK c-Jun N-terminal kinase
MAPKs mitogen-activated protein kinases
MRI magnetic resonance imaging
NCCN National Comprehensive Cancer Network
OS overall survival
PARP poly ADP ribose polymerase
PDAC pancreatic ductal adenocarcinoma
PERK protein kinase RNA-like endoplasmic reticulum kinase
PJS Peutz-Jeghers Syndrome
UP unfolded protein
UPR unfolded protein response
VEGF vascular endothelial growth factor
XBP1 transcription factor X-box 1
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